Dr. Thomas Reid, MD
Claim this profileMemorial Hospital of South Bend
Studies Ovarian Cancer
Studies Cancer
23 reported clinical trials
49 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
BRCA1
BRCA2
2Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Thomas Reid, MD is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Alpelisib + Fulvestrant
for Endometrial Cancer
This trial tests a combination of two drugs, alpelisib and fulvestrant, in patients with a specific type of endometrial cancer. These patients have a genetic mutation (PIK3CA) and their cancer grows in response to estrogen. Alpelisib targets the mutation, while fulvestrant blocks estrogen, aiming to stop cancer growth. Alpelisib is the first drug of its kind approved for use with fulvestrant based on its effectiveness in treating similar types of cancer.
Recruiting1 award Phase 210 criteria
More about Thomas Reid, MD
Clinical Trial Related2 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Thomas Reid, MD has experience with
- Carboplatin
- Pemetrexed
- Paclitaxel
- Bevacizumab
- Gemcitabine
- Pembrolizumab
Breakdown of trials Thomas Reid, MD has run
Ovarian Cancer
Cancer
Non-Small Cell Lung Cancer
Ovarian Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas Reid, MD specialize in?
Thomas Reid, MD focuses on Ovarian Cancer and Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are BRCA1.
Is Thomas Reid, MD currently recruiting for clinical trials?
Yes, Thomas Reid, MD is currently recruiting for 8 clinical trials in South Bend Indiana. If you're interested in participating, you should apply.
Are there any treatments that Thomas Reid, MD has studied deeply?
Yes, Thomas Reid, MD has studied treatments such as Carboplatin, Pemetrexed, Paclitaxel.
What is the best way to schedule an appointment with Thomas Reid, MD?
Apply for one of the trials that Thomas Reid, MD is conducting.
What is the office address of Thomas Reid, MD?
The office of Thomas Reid, MD is located at: Memorial Hospital of South Bend, South Bend, Indiana 46601 United States. This is the address for their practice at the Memorial Hospital of South Bend.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.